Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80% of all lung cancers. NSCLC 5-year survival rate is about 32% for all stages combined. First-line therapies for NSCLC have shifted from chemotherapies to targeted therapies or immunotherapy. First-line drugs for Non-Small Cell Lung Cancer (NSCLC) depend on tumor biomarkers, targeting driver mutations (like EGFR, ALK, ROS1) with specific targeted therapies (e.g., Osimertinib for EGFR, Alectinib for ALK) or using immunotherapy (Pembrolizumab, Atezolizumab) for high PD-L1 expression, often combined with chemotherapy (Platinum/Pemetrexed) if mutations are absent or PD-L1 is lower. At Vera Bio, we’re developing a new therapy that can potentially have high efficacy for many NSCLC subtypes.